<DOC>
	<DOCNO>NCT02375828</DOCNO>
	<brief_summary>The understanding molecular mechanism neonatal diabetes deeply change therapy patient carry mutation K-ATP channel . Indeed , patient treat anymore insulin injection glibenclamide oral anti-diabetic drug widely use type 2 diabetes . Anyway , galenic form ( pills 5 mg ) suitable child difficult administrate infant young child . The purpose study determine new galenic form durg suitable efficient pill child neonatal diabetes .</brief_summary>
	<brief_title>Glibentek Patients With Neonatal Diabetes Secondary Mutations K+-ATP Channels</brief_title>
	<detailed_description>Neonatal diabetes mellitus ( NDM ) , characterize hyperglycaemia require exogenous insulin therapy , rare condition appear first month life estimate incidence 1 12000 newborn . We recently publish large cohort , origin disease heterozygous activate mutation cod sequence KCNJ11 ABCC8 gene 42 % patient . These gene encode Kir 6.2 subunit ( KCNJ11 gene ) SUR1 subunit ( ABCC8 gene ) ATP-sensitive K+ channel ( KATP ) function beta cell induce membrane depolarization trigger exocytosis insulin-containing granule . The understanding molecular substrate disease deeply change therapy , allow switch insulin injection oral medication sulfonylurea . Indeed , drug specifically bind SUR1 subunit increase closing ability KATP ATP-independent mechanism stimulate insulin secretion . Together others demonstrate drug efficient replacement subcutaneous inject insulin child adult Kir6.2 SUR1 activate mutation allow excellent metabolic control disease without side effect insulin ( hypoglycemia ) . Anyway , country , glibenclamide approve use child heath authority france use temporary tolerate specific indication . Furthermore galenic form ( pill ) suitable child especially infant . The dosage high infant young child child wih neurologic defect ( frequently associate kind neonatal diabetes ) ca n't swallow pill . Chewing pill ca n't alternative sulfamides know induce alteration tooth enamel color . Most patient parent crush pill dilute powder water administrate child . Such process n't follow recommendation administration medicine contradiction . It also alter drug cinetic.as glibenclamide completely soluble water . After successful clinical trial , decide part development galenice form suitable child . The AMMtek company create new galenic dedicate pediatric patient . This new oral solution demonstrate safe effective phase 1 study . Its pediatric investigation plan validate july 2013 European medicine agency . The French drug food agency ( ANSM ) ask tolerance acceptability study give approval use child infant neonatal diabetes . The aim study determine tolerance acceptability oral solution glibenclamide ( Glinbentek ) develop dedicate pediatric patient neonatal diabetes secondary mutation potassium channel .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Age 18 year Neonatal diabetes secondary document mutation one 2 sub unit potassium channel Patients already treat glibenclamide pill Signed consent Families unable fill questionnaries Patients unable answer visual hedonic squale Patients unable take oral solution Known allergy sulfonylurea antidiabetic antibiotic sulfamides Insulin therapy associate glibenclamide Miconazole therapy Porphyria Breast feeding Severe renal failure ( creatinine clearance 30 ml/mn ) Liver failure ( prothombine time 70 ) Not affiliate health care system</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acceptability</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Neonatal diabetes</keyword>
</DOC>